VERVE-201 / Eli Lilly - LARVOL DELTA

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Verve Therapeutics, Inc. | Trial completion date: Mar 2027 ➔ Dec 2027 | Trial primary completion date: Mar 2027 ➔ Dec 2027

Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) - "Initial Data for the Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 Expected in the Second Quarter of 2025....Dosing has been completed or is ongoing in participants across the first three dose cohorts, 0.3 mg/kg, 0.45 mg/kg, and 0.6 mg/kg, in the Heart-2 clinical trial....Verve expects to report the final data for the dose escalation portion of the Heart-2 clinical trial and initiate the Phase 2 clinical trial for the PCSK9 program in the second half of 2025. Verve plans to deliver the opt-in data package for the PCSK9 program and receive a decision from Eli Lilly and Company (Lilly) in the second half of 2025....ANGPTL3 Program: Pulse-1 Phase 1b Clinical Trial for VERVE-201 Continues to Progress....Verve expects to provide an update on the ANGPTL3 program in the second half of 2025."

P1 data • Cardiovascular • Heterozygous Familial Hypercholesterolemia

Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Verve Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • Metabolic Disorders

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Verve Therapeutics, Inc.

New P1 trial • Dyslipidemia • Metabolic Disorders